Prometheus Biosciences 74348YAV3 Bond
RXDXDelisted Stock | USD 199.92 0.24 0.12% |
Prometheus Biosciences holds a debt-to-equity ratio of 0.076. With a high degree of financial leverage come high-interest payments, which usually reduce Prometheus Biosciences' Earnings Per Share (EPS).
Asset vs Debt
Equity vs Debt
Prometheus Biosciences' liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. Prometheus Biosciences' cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps Prometheus Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect Prometheus Biosciences' stakeholders.
For most companies, including Prometheus Biosciences, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for Prometheus Biosciences, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, Prometheus Biosciences' management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Prometheus |
Given the importance of Prometheus Biosciences' capital structure, the first step in the capital decision process is for the management of Prometheus Biosciences to decide how much external capital it will need to raise to operate in a sustainable way. Once the amount of financing is determined, management needs to examine the financial markets to determine the terms in which the company can boost capital. This move is crucial to the process because the market environment may reduce the ability of Prometheus Biosciences to issue bonds at a reasonable cost.
Popular Name | Prometheus Biosciences US74348YAV39 |
Equity ISIN Code | US74349U1088 |
Bond Issue ISIN Code | US74348YAV39 |
Prometheus Biosciences Outstanding Bond Obligations
Dana 575 percent | US235822AB96 | Details | |
US74348YAV39 | US74348YAV39 | Details | |
PROSPECT CAP P | US74348YDU29 | Details | |
US74348YDX67 | US74348YDX67 | Details | |
BNP Paribas FRN | USF1R15XK367 | Details | |
PROSPECT CAP P | US74348YEA55 | Details | |
US74348TAU60 | US74348TAU60 | Details | |
US74348TAT97 | US74348TAT97 | Details | |
US74348TAV44 | US74348TAV44 | Details | |
PSEC 3437 15 OCT 28 | US74348TAW27 | Details | |
PROLOGIS L P | US74340XBH35 | Details | |
PLD 4 15 SEP 28 | US74340XBX84 | Details | |
PLD 2875 15 NOV 29 | US74340XBY67 | Details | |
PLD 175 01 JUL 30 | US74340XBZ33 | Details | |
PLD 4625 15 JAN 33 | US74340XBT72 | Details | |
PLD 1625 15 MAR 31 | US74340XBS99 | Details | |
PLD 3375 15 DEC 27 | US74340XBV29 | Details | |
PLD 325 30 JUN 26 | US74340XBU46 | Details | |
US74340XBP50 | US74340XBP50 | Details | |
PROLOGIS LP | US74340XBR17 | Details | |
US74340XBQ34 | US74340XBQ34 | Details | |
US74340XBL47 | US74340XBL47 | Details | |
US74340XBJ90 | US74340XBJ90 | Details | |
US74340XBK63 | US74340XBK63 | Details | |
US74340XBN03 | US74340XBN03 | Details | |
PROLOGIS LP | US74340XBM20 | Details | |
PLD 225 15 JAN 32 | US74340XCB55 | Details | |
PLD 175 01 FEB 31 | US74340XCA72 | Details | |
PLD 305 01 MAR 50 | US74340XCC39 | Details |
Understaning Prometheus Biosciences Use of Financial Leverage
Understanding the structure of Prometheus Biosciences' debt obligations provides insight if it is worth investing in it. Financial leverage can amplify the potential profits to Prometheus Biosciences' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its cost of debt.
Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases . Prometheus Biosciences, Inc. was incorporated in 2016 and is headquartered in San Diego, California. Prometheus Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 72 people. Please read more on our technical analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as various price indices. You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Other Consideration for investing in Prometheus Stock
If you are still planning to invest in Prometheus Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Prometheus Biosciences' history and understand the potential risks before investing.
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules |
What is Financial Leverage?
Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.Leverage and Capital Costs
The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.Benefits of Financial Leverage
Leverage provides the following benefits for companies:- Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
- It provides a variety of financing sources by which the firm can achieve its target earnings.
- Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.